TRP_1170x120_12-19-19

CutisPharma appoints chief scientific officer

Print Friendly, PDF & Email
WILMINGTON, Mass.Steven Dinh has joined CutisPharma as executive vice president and chief scientific officer.

CutisPharma said Monday that Dinh will play a key role at the company, overseeing its efforts to develop its pipeline of drugs for New Drug Application (NDA) submission to the Food and Drug Administration.

Steven Dinh_CutisPharma

Steven Dinh

“We are pleased to have Steven join our team at a key moment in our company’s history,” stated CutisPharma chief executive officer Neal Muni. “Steven’s experience and leadership will better position us to execute on our R&D portfolio strategy and achieve our goal of obtaining regulatory approval for our expanding portfolio of drugs.”

With more than 35 years of pharmaceutical industry experience, Dinh most recently served as vice president and chief scientific officer at Noven Pharmaceuticals. He also has held leadership roles at E.I. Dupont de Nemours & Co., Ciba-Geigy (Novartis) and Emisphere Technologies. In those posts, he spearheaded five NDA approvals and two Abbreviated New Drug Application (ANDA) filings, as well as transitioned four projects into Phase 3 development, according to CutisPharma.

Dinh also is a fellow of the American Association of Pharmaceutical Scientists and the American Institute for Medical and Biological Engineering.

“I am thrilled to be joining the CutisPharma team,” Dinh commented. “CutisPharma has been a leading developer of innovative products for the pharmacy compounding market, and I am pleased to lead the company’s transition toward bringing a new portfolio of drugs through the development process for NDA submission.”

Recently, CutisPharma has moved to transition its business from its historical base in the pharmacy compounding toward development and commercialization of FDA-approved drugs.

In March, the company announced the opening of a state-of-the-art manufacturing center at its Wilmington, Mass., facility and the completion of activities to prepare the first NDA filing of its lead pipeline drug, RM-01, next year. And in April, CutisPharma unveiled a partnership with Dr. Reddy’s Laboratories, which the company said will expedite the FDA approval process for three other drugs: RM-02, RM-03 and RM-06.


NT_728x90_10-3-18

INNOV_728x90_2-26-20

Comments are closed.